Cargando…
Novel Treatments of Uveal Melanoma Identified with a Synthetic Lethal CRISPR/Cas9 Screen
SIMPLE SUMMARY: We performed a CRISPR-Cas9 synthetic lethality screen in order to identify molecular targets whose inhibition would synergistically enhance the effect of everolimus in uveal melanoma cells. IGF1R and PRKDC, among others, were identified as hits. We verified these hits effects genetic...
Autores principales: | Glinkina, Kseniya, Groenewoud, Arwin, Teunisse, Amina F. A. S., Snaar-Jagalska, B. Ewa, Jochemsen, Aart G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264875/ https://www.ncbi.nlm.nih.gov/pubmed/35804957 http://dx.doi.org/10.3390/cancers14133186 |
Ejemplares similares
-
Combined Mcl-1 and YAP1/TAZ inhibition for treatment of metastatic uveal melanoma
por: Glinkina, Kseniya A., et al.
Publicado: (2023) -
Zebrafish Patient-Derived Xenograft Model as a Preclinical Platform for Uveal Melanoma Drug Discovery
por: Yin, Jie, et al.
Publicado: (2023) -
Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022) -
Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
por: Groenewoud, Arwin, et al.
Publicado: (2023) -
Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target
por: Cao, Jinfeng, et al.
Publicado: (2018)